Top Markets
Coin of the day
Seaport Therapeutics, Inc. Common Stock Seaport Therapeutics, Inc. Common Stock

Seaport Therapeutics, Inc. Common Stock

SPTX
Classificação em ações #8294
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise... Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Preço da ação
$24.37
Valor de mercado
$1.30B
Variação (1 dia)
-7.16%
Variação (1 ano)
-
País
US
Negociar Seaport Therapeutics, Inc. Common Stock (SPTX)

Categoria

Receita da Seaport Therapeutics, Inc. Common Stock (SPTX)
Receita em Aug 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Seaport Therapeutics, Inc. Common Stock, a receita atual da empresa (TTM) é 0. Em 2026, a empresa obteve uma receita de 0 igual a a receita do ano 2026, que foi de 0. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Seaport Therapeutics, Inc. Common Stock de 2026 a 2026
Receita no final de cada ano
Ano Receita Alterar
Não há dados suficientes para as datas fornecidas.
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
$12.62B -
US
$6.02B -
NL
$15.74B -
AU
$2.23B -
US
- -
CH